OPTIMIZING CHIMERIC ANTIGEN RECEPTOR (CAR) ENGINEERED NK CELL-MEDIATED CYTOTOXICITY COMBINED WITH ANTI-CD 20 OR ANTI-CD79 THERAPEUTIC ANTIBODIES AND NKTR-255 IN BURKITT LYMPHOMA (BL). (October 2022)